JP2011500844A5 - - Google Patents

Download PDF

Info

Publication number
JP2011500844A5
JP2011500844A5 JP2010531276A JP2010531276A JP2011500844A5 JP 2011500844 A5 JP2011500844 A5 JP 2011500844A5 JP 2010531276 A JP2010531276 A JP 2010531276A JP 2010531276 A JP2010531276 A JP 2010531276A JP 2011500844 A5 JP2011500844 A5 JP 2011500844A5
Authority
JP
Japan
Prior art keywords
fluid
ppm
specifically
item
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010531276A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011500844A (ja
JP5911197B2 (ja
Filing date
Publication date
Priority claimed from PCT/US2007/082578 external-priority patent/WO2008052143A2/en
Priority claimed from PCT/US2007/082580 external-priority patent/WO2008052145A2/en
Priority claimed from PCT/US2007/082581 external-priority patent/WO2008115290A2/en
Application filed filed Critical
Priority claimed from PCT/US2008/081113 external-priority patent/WO2009055671A1/en
Publication of JP2011500844A publication Critical patent/JP2011500844A/ja
Publication of JP2011500844A5 publication Critical patent/JP2011500844A5/ja
Application granted granted Critical
Publication of JP5911197B2 publication Critical patent/JP5911197B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010531276A 2007-10-25 2008-10-24 嚢胞性線維症を治療するための組成物および方法 Expired - Fee Related JP5911197B2 (ja)

Applications Claiming Priority (19)

Application Number Priority Date Filing Date Title
US98272007P 2007-10-25 2007-10-25
US98271907P 2007-10-25 2007-10-25
US60/982,719 2007-10-25
USPCT/US2007/082581 2007-10-25
USPCT/US2007/082580 2007-10-25
PCT/US2007/082578 WO2008052143A2 (en) 2006-10-25 2007-10-25 Mixing device and output fluids of same
US60/982,720 2007-10-25
PCT/US2007/082580 WO2008052145A2 (en) 2006-10-25 2007-10-25 Methods of therapeutic treatment of eyes and other human tissues using an oxygen-enriched solution
PCT/US2007/082581 WO2008115290A2 (en) 2006-10-25 2007-10-25 Methods of wound care and treatment
USPCT/US2007/082578 2007-10-25
US4834008P 2008-04-28 2008-04-28
US4840408P 2008-04-28 2008-04-28
US4833208P 2008-04-28 2008-04-28
US4834708P 2008-04-28 2008-04-28
US61/048,404 2008-04-28
US61/048,340 2008-04-28
US61/048,347 2008-04-28
US61/048,332 2008-04-28
PCT/US2008/081113 WO2009055671A1 (en) 2007-10-25 2008-10-24 Compositions and methods for treating cystic fibrosis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014117564A Division JP2014193915A (ja) 2007-10-25 2014-06-06 嚢胞性線維症を治療するための組成物および方法

Publications (3)

Publication Number Publication Date
JP2011500844A JP2011500844A (ja) 2011-01-06
JP2011500844A5 true JP2011500844A5 (https=) 2012-12-06
JP5911197B2 JP5911197B2 (ja) 2016-04-27

Family

ID=42261767

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2010531255A Expired - Fee Related JP5613565B2 (ja) 2007-10-25 2008-10-23 細胞膜媒介細胞内シグナル伝達を調節するための組成物および方法
JP2010531276A Expired - Fee Related JP5911197B2 (ja) 2007-10-25 2008-10-24 嚢胞性線維症を治療するための組成物および方法
JP2010531290A Active JP5869763B2 (ja) 2007-10-25 2008-10-24 炎症を治療するための組成物および方法
JP2014117564A Pending JP2014193915A (ja) 2007-10-25 2014-06-06 嚢胞性線維症を治療するための組成物および方法
JP2014121357A Withdrawn JP2014205693A (ja) 2007-10-25 2014-06-12 細胞膜媒介細胞内シグナル伝達を調節するための組成物および方法
JP2014121350A Withdrawn JP2014169328A (ja) 2007-10-25 2014-06-12 炎症を治療するための組成物および方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2010531255A Expired - Fee Related JP5613565B2 (ja) 2007-10-25 2008-10-23 細胞膜媒介細胞内シグナル伝達を調節するための組成物および方法

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2010531290A Active JP5869763B2 (ja) 2007-10-25 2008-10-24 炎症を治療するための組成物および方法
JP2014117564A Pending JP2014193915A (ja) 2007-10-25 2014-06-06 嚢胞性線維症を治療するための組成物および方法
JP2014121357A Withdrawn JP2014205693A (ja) 2007-10-25 2014-06-12 細胞膜媒介細胞内シグナル伝達を調節するための組成物および方法
JP2014121350A Withdrawn JP2014169328A (ja) 2007-10-25 2014-06-12 炎症を治療するための組成物および方法

Country Status (8)

Country Link
EP (3) EP2215260A4 (https=)
JP (6) JP5613565B2 (https=)
CN (5) CN101910412B (https=)
AU (3) AU2008316794B2 (https=)
CA (3) CA2703672A1 (https=)
IL (3) IL205319A (https=)
MX (3) MX2010004563A (https=)
WO (1) WO2009055614A1 (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6702949B2 (en) 1997-10-24 2004-03-09 Microdiffusion, Inc. Diffuser/emulsifier for aquaculture applications
US8445546B2 (en) 2006-10-25 2013-05-21 Revalesio Corporation Electrokinetically-altered fluids comprising charge-stabilized gas-containing nanostructures
AU2007308838B2 (en) 2006-10-25 2014-03-13 Revalesio Corporation Mixing device and output fluids of same
US8597689B2 (en) 2006-10-25 2013-12-03 Revalesio Corporation Methods of wound care and treatment
US10125359B2 (en) 2007-10-25 2018-11-13 Revalesio Corporation Compositions and methods for treating inflammation
MX2010004549A (es) * 2007-10-25 2010-07-28 Revalesio Corp Composiciones y métodos bacteriostáticos o bactericidas.
EP2215260A4 (en) * 2007-10-25 2011-04-20 Revalesio Corp COMPOSITIONS AND METHOD FOR MODULATING CELL MEMBRANE-IMPROVED INTRA-CELLULAR SIGNAL TRANSMISSION
US9523090B2 (en) 2007-10-25 2016-12-20 Revalesio Corporation Compositions and methods for treating inflammation
US9745567B2 (en) 2008-04-28 2017-08-29 Revalesio Corporation Compositions and methods for treating multiple sclerosis
AU2009241365B2 (en) * 2008-04-28 2015-01-22 Revalesio Corporation Compositions and methods for treating multiple sclerosis
US8980325B2 (en) 2008-05-01 2015-03-17 Revalesio Corporation Compositions and methods for treating digestive disorders
CA2741336A1 (en) * 2008-10-22 2010-04-29 Revalesio Corporation Compositions and methods for treating thymic stromal lymphopoietin (tslp)-mediated conditions
AU2010241736B2 (en) * 2009-04-27 2016-01-28 Revalesio Corporation Compositions and methods for treating insulin resistance and diabetes mellitus
US8815292B2 (en) 2009-04-27 2014-08-26 Revalesio Corporation Compositions and methods for treating insulin resistance and diabetes mellitus
BR112012028540A2 (pt) * 2010-05-07 2016-07-26 Revalesio Corp composições e métodos para melhorar desempenho fisiológico e tempo de recuperação
KR20130050952A (ko) 2010-06-16 2013-05-16 브루스 챈들러 메이 인플루엔자, 감기 및 염증의 치료에서 레보세티리진 및 몬테루카스트의 용도
JP2013533320A (ja) 2010-08-12 2013-08-22 レバレジオ コーポレイション タウオパチーを治療するための組成物および方法
KR20130100126A (ko) * 2010-08-13 2013-09-09 레발레시오 코퍼레이션 심혈관 질환을 치료하기 위한 조성물 및 방법
US20120263764A1 (en) * 2011-04-13 2012-10-18 Revalesio Corporation Compositions and methods for inhibiting and/or modulating effector t-cells involved in inflammatory neurodegenerative disease
JP6368459B2 (ja) * 2012-06-14 2018-08-01 松本　高明 点眼液の製造方法
RU2015134423A (ru) 2013-03-13 2017-04-26 Инфламматори Респонс Ресёрч, Инк. Применение левоцитиризина и монтелукаста при лечении аутоиммуных расстройств
MX382776B (es) 2013-03-13 2025-03-13 Inflammatory Response Res Inc Uso de levocetirizina y montelukast en el tratamiento de lesion traumatica.
WO2014164285A2 (en) 2013-03-13 2014-10-09 Inflammatory Response Research, Inc. Use of levocetirizine and montelukast in the treatment of vasculitis
WO2016044095A1 (en) 2014-09-15 2016-03-24 Inflammatory Response Research, Inc. Levocetirizine and montelukast in the treatment of inflammation mediated conditions
CN106943593A (zh) * 2017-03-24 2017-07-14 浙江中医药大学 抗tslp抗体在制备防治慢性瘙痒药物中的应用
CA3064050A1 (en) * 2017-05-23 2018-11-29 Biovite Australia Pty Ltd. Extracts from arthrospira and uses thereof
WO2021236518A1 (en) 2020-05-19 2021-11-25 IRR, Inc. Levocetirizine and montelukast in the treatment of sepsis and symptoms thereof
CN112305153B (zh) * 2020-10-16 2022-09-23 中石化石油工程技术服务有限公司 一种膨润土含量的自动分析检测仪及其检测方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9518483D0 (en) * 1995-09-09 1995-11-08 Thompson Royce Ltd Lighting control systems
US7654728B2 (en) * 1997-10-24 2010-02-02 Revalesio Corporation System and method for therapeutic application of dissolved oxygen
US6386751B1 (en) * 1997-10-24 2002-05-14 Diffusion Dynamics, Inc. Diffuser/emulsifier
EP1100811B1 (en) * 1998-07-28 2007-07-04 The Regents Of The University Of California Nucleic acids encoding a g-protein coupled receptor involved in sensory transduction
EP1237578A4 (en) * 1999-10-26 2004-10-27 Bio Hydration Res Lab Inc MICRO-AGGREGATED LIQUIDS AND METHODS OF MAKING AND USING SAME
US20060198901A9 (en) * 1999-10-26 2006-09-07 Holloway William D Jr Drugs, bio-affecting and body treating compositions
WO2001042451A2 (en) * 1999-12-08 2001-06-14 Genset FULL-LENGTH HUMAN cDNAs ENCODING POTENTIALLY SECRETED PROTEINS
US7255881B2 (en) * 2000-07-27 2007-08-14 Nucryst Pharmaceuticals Corp. Metal-containing materials
WO2002024222A2 (en) * 2000-09-20 2002-03-28 The Cleveland Clinic Foundation Ligands for g protein coupled receptors and methods of using them
US20040235732A1 (en) * 2000-11-03 2004-11-25 Qun-Yong Zhou Method for modulating angiogenesis using prokineticin receptor antagonists
EP1357920B1 (en) * 2001-02-01 2007-09-05 Hydron Technologies Inc. Compositions and method of tissue superoxygenation
GB0118383D0 (en) * 2001-07-27 2001-09-19 Pharmagene Lab Ltd Therapeutic methods
DE10227818A1 (de) * 2002-06-21 2004-01-08 Pakdaman, Abolghassem, Prof. Dr.med. Gasanreicherungsmodule
AU2002321678A1 (en) * 2002-09-09 2004-03-29 Boros Béla Oxygen-enriched water, treated within a magnetic field and heavy water
US7790762B2 (en) * 2002-10-31 2010-09-07 National Jewish Health Compounds and methods for thiol-containing compound efflux and cancer treatment
US7491695B2 (en) * 2003-06-18 2009-02-17 Tranzyme Pharma Inc. Methods of using macrocyclic modulators of the ghrelin receptor
ATE500234T1 (de) * 2003-11-10 2011-03-15 Merck Sharp & Dohme Substituierte trialzole als blocker des natriumkanals
US20050139808A1 (en) * 2003-12-30 2005-06-30 Oculus Innovative Sciences, Inc. Oxidative reductive potential water solution and process for producing same
US20060073212A1 (en) * 2004-04-22 2006-04-06 Palmer Craig R Method of treating respiratory disorders and airway inflammation
AU2005329764B2 (en) * 2005-03-28 2010-08-12 Dabur Pharma Ltd. Stable pharmaceutical compositions of platinum (II) antitumour agents
EP1901749B1 (en) * 2005-05-18 2016-08-03 Raptor Pharmaceuticals Inc. Aerosolized fluoroquinolones and uses thereof
GB0603683D0 (en) * 2006-02-23 2006-04-05 Novartis Ag Organic compounds
US8597689B2 (en) * 2006-10-25 2013-12-03 Revalesio Corporation Methods of wound care and treatment
AU2007308838B2 (en) * 2006-10-25 2014-03-13 Revalesio Corporation Mixing device and output fluids of same
JP5491185B2 (ja) * 2006-10-25 2014-05-14 リバルシオ コーポレイション 傷のケアおよび処置の方法
MX2010004549A (es) * 2007-10-25 2010-07-28 Revalesio Corp Composiciones y métodos bacteriostáticos o bactericidas.
EP2215260A4 (en) * 2007-10-25 2011-04-20 Revalesio Corp COMPOSITIONS AND METHOD FOR MODULATING CELL MEMBRANE-IMPROVED INTRA-CELLULAR SIGNAL TRANSMISSION

Similar Documents

Publication Publication Date Title
JP2011500844A5 (https=)
Wang et al. The density of surface coating can contribute to different antibacterial activities of gold nanoparticles
Tarran et al. The CF salt controversy: in vivo observations and therapeutic approaches
Dakal et al. Mechanistic basis of antimicrobial actions of silver nanoparticles
JP2011500838A5 (https=)
RU2657510C2 (ru) Системы для лечения легочных инфекций
Seo et al. Engineering copper nanoparticles synthesized on the surface of carbon nanotubes for anti-microbial and anti-biofilm applications
JP5675096B2 (ja) 肺の疾患の酵素的処置のための組成物及び方法
Wills et al. Sodium chloride increases the ciliary transportability of cystic fibrosis and bronchiectasis sputum on the mucus-depleted bovine trachea.
Cavalieri et al. Nanomedicines for antimicrobial interventions
JP2011500837A5 (https=)
ME00597B (me) Produženo otpuštanje antiinfektivnih sredstava
CN107072944A (zh) 具有抗非结核分枝杆菌活性的脂质体环丙沙星制剂
Tewes et al. Ciprofloxacin-loaded inorganic–organic composite microparticles to treat bacterial lung infection
Verma et al. Inhalable microparticles containing nitric oxide donors: saying NO to intracellular Mycobacterium tuberculosis
Luan et al. Cystic fibrosis swine fail to secrete airway surface liquid in response to inhalation of pathogens
KR101421765B1 (ko) 의료용 용매화 시스템 및 실런트
US12533374B2 (en) Compositions and methods of use thereof
Kuwabara et al. Healing of Pseudomonas aeruginosa-infected wounds in diabetic db/db mice by weakly acidic hypochlorous acid cleansing and silver nanoparticle/chitin-nanofiber sheet covering
Popova et al. In vitro antimicrobial activity of colloidal nano silver.
AU2025248660A1 (en) Amino acid compositions and methods for treating cystic fibrosis
Flume et al. The rationale for aerosolized antibiotics
Ojano-Dirain et al. Biofilm formation on coated silicone tympanostomy tubes
US20210252048A1 (en) Treatment of lung and airway diseases and disorders
DE19632014A1 (de) Die Mikroklimatische Salinenkammer (MSK)